Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2012

View Archived Issues

Xention identifies novel ion channel blockers for atrial fibrillation

Seachaid Pharmaceuticals compounds active against Gram-positive bacteria

Opaxio receives FDA orphan drug designation

Coyote Pharmaceuticals plans clinical program with CNS-102

Encouraging phase III results for rFIXFc in hemophilia B

Pfizer discloses new antibacterial agents

Novel TRPM8 channel antagonists presented by Pfizer

PAC-14028 evaluated as a treatment for pruritus

The Vanderbilt University patents new mGlu5 receptor allosteric modulators

Czech scientists report novel dual PGE2 and NO production inhibitors

NuCana BioMed synthesizes new thymidylate synthase inhibitors

Phase IIb study of NBI-98854 in tardive dyskinesia commences

Eliglustat tartrate meets primary endpoint in phase III trial in Gaucher's disease

FDA panel recommends approval of Argus II Retinal Prosthesis System

Acacia Pharma reports results from phase IIa APD-403 study

IND cleared for Omeros' lead PDE10 candidate

NIAID grant awarded to AvidBiotics for antibacterial proteins

Diacomit approved in Japan for Dravet syndrome

Japanese approval granted for Buphenyl for urea cycle disorders

Delamanid can be administered with efavirenz

GTx sells Fareston

SBIR grant supports Colby Pharmaceutical's work in prostate cancer

ArQule and Daiichi Sankyo discontinue phase III MARQUEE trial

NDA submitted for vortioxetine for major depressive disorder

Janssen licenses rights to Astellas' oral JAK inhibitor

U.S. government awards GeoVax a grant for its HIV vaccine program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...